ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

China · Delayed Price · Currency is CNY

35.60

-0.88 (-2.41%)

Apr 9, 2026, 3:00 PM CST

70.69% (1Y)

Market Cap	5.60B +121.4%
Revenue (ttm)	741.34M +62.6%
Net Income	165.82M +231.5%
EPS	1.05 +234.1%
Shares Out	157.39M
PE Ratio	33.90
Forward PE	20.70
Dividend	0.06 (0.17%)
Ex-Dividend Date	Nov 17, 2025

Volume	2,431,275
Average Volume	2,988,650
Open	36.38
Previous Close	36.48
Day's Range	35.40 - 36.66
52-Week Range	17.94 - 47.97
Beta	0.74
RSI	47.89
Earnings Date	Apr 24, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. Che... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2001

Employees 1,450

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688117

Full Company Profile

Financial Performance

In 2025, ChengDu ShengNuo Biotec's revenue was 741.34 million, an increase of 62.55% compared to the previous year's 456.07 million. Earnings were 165.82 million, an increase of 231.49%.

Financial Statements